Cytosorbents (CTSO) Share-based Compensation Growth (5y) (2015 - 2026)
Cytosorbents (CTSO) Share-based Compensation Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.65 Bn | 175.35 Bn | 6.27 Bn |
| 2 | Stryker | 128.95 Bn | 126.08 Bn | 3.81 Bn |
| 3 | Medtronic | 108.30 Bn | 99.08 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.31 Bn | 66.85 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.19 Bn | 44.52 Bn | 1.29 Bn |
| 6 | Dexcom | 28.33 Bn | 27.21 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.02 Bn | 25.74 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.97 Bn | 26.39 Bn | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn |
| 10 | Cytosorbents | 22.27 Mn | 17.47 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.98% |
| Dec 31, 2025 | 34.81% |
| Sep 30, 2025 | 14.06% |
| Jun 30, 2025 | -11.40% |
| Mar 31, 2025 | 2.32% |
| Dec 31, 2024 | 4.22% |
| Sep 30, 2024 | 2.13% |
| Jun 30, 2024 | 46.81% |
| Mar 31, 2024 | -65.69% |
| Dec 31, 2023 | 19.73% |
| Sep 30, 2023 | 31.71% |
| Jun 30, 2023 | -22.71% |
| Mar 31, 2023 | 23.11% |
| Dec 31, 2022 | -22.47% |
| Sep 30, 2022 | 651.25% |
| Jun 30, 2022 | 45.86% |
| Mar 31, 2022 | 53.52% |
| Dec 31, 2021 | -50.97% |
| Sep 30, 2021 | 6.65% |
| Dec 31, 2020 | 22.55% |